We have developed a novel DT-DEC01 therapy, which is based on Dystrophin Expressing Chimeric (DEC) cells created by fusing human myoblasts derived from normal (allogeneic) and DMD-affected (autologous) donors. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.